Separating the equipment lease from the service component in managed equipment placement contracts

Vendor-managed equipment placement arrangements are structured to look like a pure supply agreement but frequently contain an embedded lease that, if unrecognized, understates both assets and liabilities and misclassifies the true nature of the reagent/consumable spend, which can distort both the balance sheet and the cost structure users rely on to assess the entity's real capital commitments.

Does the contract convey the right to control the use of an identified piece of equipment for a period, or does the supplier retain a substantive right to substitute the equipment, effectively delivering a pure service instead of a lease? Can the lease and non-lease components, such as maintenance, reagents and consumables, be separated based on observable standalone prices? Is reagent or consumable pricing structured to recover the cost of equipment placement, indicating an embedded financing or lease element hidden within the supply price?

1) Determine whether the contract conveys the right to control the use of an identified piece of equipment for a period of time (a specific analyzer, not a class of interchangeable machines the supplier can freely substitute). 2) Assess whether the supplier retains a substantive right of substitution (would need both the practical ability and an economic benefit from substituting); if so, no lease component exists and the arrangement is a pure service/supply contract. 3) Where an identified asset and control exist, separate lease payments (or an allocated portion of a bundled fee) from non-lease service/supply components using observable standalone prices for equipment rental and for reagent/consumable supply separately. 4) Recognize a right-of-use asset and lease liability for the identified lease component at commencement, following the same recognition mechanics as any other IFRS 16 lease. 5) Account for the service/supply elements (reagents, maintenance) under IFRS 15/inventory guidance as those goods/services are delivered. 6) Reassess the arrangement if reagent volumes fall materially short of committed levels, which may signal an onerous element or a change requiring remeasurement.

Allocate the consideration in a bundled placement arrangement between the lease and non-lease components based on relative standalone prices (observable market rates for equipment rental and for reagent/consumable supply separately) where the practical expedient to combine components is not elected or not available; measure the lease liability at the present value of the allocated lease payments using an appropriate discount rate, consistent with the general IFRS 16 measurement approach.

Disclose the nature of equipment placement arrangements and the basis used to separate lease and service/supply components; disclose the resulting right-of-use asset and lease liability recognized (if the hospital is the lessee) or lease income policy (if the entity places equipment as lessor); disclose any onerous contract indicators arising from reagent volume shortfalls against committed levels.

• Treating the entire reagent/consumable purchase commitment as a straightforward inventory purchase without recognizing an embedded lease for the placed equipment, understating assets and liabilities
• expensing bundled placement fees entirely as a service cost without recognizing a right-of-use asset and lease liability where a lease component exists
• failing to reassess the arrangement when reagent volumes fall materially short of committed levels, which may signal an onerous element
• using the full reagent invoice price as inventory cost without separating out the embedded financing/lease element.